Cargando…

Subtractive Genomics Approach for Identification of Novel Therapeutic Drug Targets in Mycoplasma genitalium

Mycoplasma genitalium infection is a sexually transmitted infection that causes urethritis, cervicitis, and pelvic inflammatory disease (PID) in men and women. The global rise in antimicrobial resistance against recommended antibiotics for the treatment of M. genitalium infection has triggered the n...

Descripción completa

Detalles Bibliográficos
Autores principales: Fatoba, Abiodun Joseph, Okpeku, Moses, Adeleke, Matthew Adekunle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402164/
https://www.ncbi.nlm.nih.gov/pubmed/34451385
http://dx.doi.org/10.3390/pathogens10080921
_version_ 1783745722745618432
author Fatoba, Abiodun Joseph
Okpeku, Moses
Adeleke, Matthew Adekunle
author_facet Fatoba, Abiodun Joseph
Okpeku, Moses
Adeleke, Matthew Adekunle
author_sort Fatoba, Abiodun Joseph
collection PubMed
description Mycoplasma genitalium infection is a sexually transmitted infection that causes urethritis, cervicitis, and pelvic inflammatory disease (PID) in men and women. The global rise in antimicrobial resistance against recommended antibiotics for the treatment of M. genitalium infection has triggered the need to explore novel drug targets against this pathogen. The application of a bioinformatics approach through subtractive genomics has proven highly instrumental in predicting novel therapeutic targets against a pathogen. This study aimed to identify essential and non-homologous proteins with unique metabolic pathways in the pathogen that could serve as novel drug targets. Based on this, a manual comparison of the metabolic pathways of M. genitalium and the human host was done, generating nine pathogen-specific metabolic pathways. Additionally, the analysis of the whole proteome of M. genitalium using different bioinformatics databases generated 21 essential, non-homologous, and cytoplasmic proteins involved in nine pathogen-specific metabolic pathways. The further screening of these 21 cytoplasmic proteins in the DrugBank database generated 13 druggable proteins, which showed similarity with FDA-approved and experimental small-molecule drugs. A total of seven proteins that are involved in seven different pathogen-specific metabolic pathways were finally selected as novel putative drug targets after further analysis. Therefore, these proposed drug targets could aid in the design of potent drugs that may inhibit the functionality of these pathogen-specific metabolic pathways and, as such, lead to the eradication of this pathogen.
format Online
Article
Text
id pubmed-8402164
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84021642021-08-29 Subtractive Genomics Approach for Identification of Novel Therapeutic Drug Targets in Mycoplasma genitalium Fatoba, Abiodun Joseph Okpeku, Moses Adeleke, Matthew Adekunle Pathogens Article Mycoplasma genitalium infection is a sexually transmitted infection that causes urethritis, cervicitis, and pelvic inflammatory disease (PID) in men and women. The global rise in antimicrobial resistance against recommended antibiotics for the treatment of M. genitalium infection has triggered the need to explore novel drug targets against this pathogen. The application of a bioinformatics approach through subtractive genomics has proven highly instrumental in predicting novel therapeutic targets against a pathogen. This study aimed to identify essential and non-homologous proteins with unique metabolic pathways in the pathogen that could serve as novel drug targets. Based on this, a manual comparison of the metabolic pathways of M. genitalium and the human host was done, generating nine pathogen-specific metabolic pathways. Additionally, the analysis of the whole proteome of M. genitalium using different bioinformatics databases generated 21 essential, non-homologous, and cytoplasmic proteins involved in nine pathogen-specific metabolic pathways. The further screening of these 21 cytoplasmic proteins in the DrugBank database generated 13 druggable proteins, which showed similarity with FDA-approved and experimental small-molecule drugs. A total of seven proteins that are involved in seven different pathogen-specific metabolic pathways were finally selected as novel putative drug targets after further analysis. Therefore, these proposed drug targets could aid in the design of potent drugs that may inhibit the functionality of these pathogen-specific metabolic pathways and, as such, lead to the eradication of this pathogen. MDPI 2021-07-21 /pmc/articles/PMC8402164/ /pubmed/34451385 http://dx.doi.org/10.3390/pathogens10080921 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fatoba, Abiodun Joseph
Okpeku, Moses
Adeleke, Matthew Adekunle
Subtractive Genomics Approach for Identification of Novel Therapeutic Drug Targets in Mycoplasma genitalium
title Subtractive Genomics Approach for Identification of Novel Therapeutic Drug Targets in Mycoplasma genitalium
title_full Subtractive Genomics Approach for Identification of Novel Therapeutic Drug Targets in Mycoplasma genitalium
title_fullStr Subtractive Genomics Approach for Identification of Novel Therapeutic Drug Targets in Mycoplasma genitalium
title_full_unstemmed Subtractive Genomics Approach for Identification of Novel Therapeutic Drug Targets in Mycoplasma genitalium
title_short Subtractive Genomics Approach for Identification of Novel Therapeutic Drug Targets in Mycoplasma genitalium
title_sort subtractive genomics approach for identification of novel therapeutic drug targets in mycoplasma genitalium
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402164/
https://www.ncbi.nlm.nih.gov/pubmed/34451385
http://dx.doi.org/10.3390/pathogens10080921
work_keys_str_mv AT fatobaabiodunjoseph subtractivegenomicsapproachforidentificationofnoveltherapeuticdrugtargetsinmycoplasmagenitalium
AT okpekumoses subtractivegenomicsapproachforidentificationofnoveltherapeuticdrugtargetsinmycoplasmagenitalium
AT adelekematthewadekunle subtractivegenomicsapproachforidentificationofnoveltherapeuticdrugtargetsinmycoplasmagenitalium